Last reviewed · How we verify
NCT03762707
Correlation Between Platelet Function Analyzer-100 Testing and Bleeding Events After Percutaneous Kidney Biopsy
trial in Blood Platelet Disorder in 250 participants. Status unknown.
1 July 2019
Quick facts
| Lead sponsor | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 13 June 2019 |
| Primary completion | 1 July 2019 |
| Estimated completion | 1 September 2019 |
| Sites | 1 location across Italy |
Conditions studied
- Blood Platelet Disorder — all drugs for Blood Platelet Disorder →
- Hemorrhage — all drugs for Hemorrhage →
- Kidney Diseases — all drugs for Kidney Diseases →
Sponsor
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Who can join
Adults 18 to 85, any sex, with Blood Platelet Disorder or Hemorrhage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Kidney biopsy represents the criterion standard to obtain information on diagnosis and prognosis of renal dysfunctions . Many patients with kidney disease have a predisposition to bleed, especially when they undergo an invasive procedure such as renal biopsy. The predominant factor is abnormal platelet function. Therefore, the aim of this study is to evaluate whether the platelet function analyzer (PFA-100), a very reliable test to investigate primary hemostasis, can be useful in predicting the risk of bleeding complications in patients undergoing renal biopsy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03762707
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Blood Platelet Disorder
Currently open trials in the same condition.
- NCT06539702 — Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology. · recruiting
Other Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari trials
Trials by the same sponsor.
- NCT06812611 — Effects of High Intensity Laser Therapy in Muscle Injuries · NA · recruiting
- NCT07566507 — High-Energy Laser in the Conservative Treatment of Rhizarthrosis · NA · recruiting
- NCT06833372 — Shock Waves in Knee Arthritis · NA · recruiting
- NCT06737601 — ESWT vs Orthosis in Trigger Finger · NA · not yet recruiting
- NCT07185555 — Vey Low-Energy Ketogenic Therapy in Adults With Type 1 Diabetes and Obesity on Intensive Insulin Therapy Using Advanded · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03762707 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
- Last refreshed: 18 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03762707.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing